Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Randomized Double-Blind Placebo-Controlled Multiple-Dose 3-Period Crossover Study to Compare a Fixed Dose Combination of AD816 to Viloxazine Alone and to Placebo in Obstructive Sleep Apnea

Next Previous
Search
Trial Profile

Phase 2 Randomized Double-Blind Placebo-Controlled Multiple-Dose 3-Period Crossover Study to Compare a Fixed Dose Combination of AD816 to Viloxazine Alone and to Placebo in Obstructive Sleep Apnea

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trazodone/viloxazine-Apnimed (Primary) ; Viloxazine
  • Indications Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Acronyms VicTor
  • Sponsors Apnimed

    • Most Recent Events

    • 23 May 2024 According to an Apnimed media release, the company announced a series of five data presentations and a dinner symposium at the SLEEP 2024 annual meeting.
    • 14 Nov 2023 Status changed from active, no longer recruiting to completed.
    • 06 Sep 2023 Planned End Date changed from 30 Aug 2023 to 30 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top